JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

Smith & Nephew PLC ADR

Geschlossen

36.8 2.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.7

Max

36.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

100M

296M

Verkäufe

4.7M

3B

KGV

Branchendurchschnitt

32.75

37.003

Dividendenrendite

2.08

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

6.5M

723M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-2.09% downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.08%

2.25%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.1B

16B

Vorheriger Eröffnungskurs

34.01

Vorheriger Schlusskurs

36.8

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Nov. 2025, 22:13 UTC

Ergebnisse

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2. Nov. 2025, 21:23 UTC

Ergebnisse

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2. Nov. 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2. Nov. 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Business Lending Up 15% on Year>WBC.AU

2. Nov. 2025, 20:46 UTC

Ergebnisse

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2. Nov. 2025, 20:46 UTC

Ergebnisse

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2. Nov. 2025, 20:45 UTC

Ergebnisse

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2. Nov. 2025, 20:44 UTC

Ergebnisse

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2. Nov. 2025, 20:43 UTC

Ergebnisse

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2. Nov. 2025, 20:42 UTC

Ergebnisse

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2. Nov. 2025, 20:41 UTC

Ergebnisse

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2. Nov. 2025, 20:40 UTC

Ergebnisse

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2. Nov. 2025, 20:39 UTC

Ergebnisse

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2. Nov. 2025, 20:36 UTC

Ergebnisse

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2. Nov. 2025, 20:34 UTC

Ergebnisse

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2. Nov. 2025, 20:33 UTC

Ergebnisse

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2. Nov. 2025, 14:27 UTC

Ergebnisse

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2. Nov. 2025, 14:25 UTC

Ergebnisse

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

-2.09% Nachteil

12-Monats-Prognose

Durchschnitt 36.05 USD  -2.09%

Hoch 37.5 USD

Tief 34.65 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

3 ratings

0

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat